Aurinia Pharmaceuticals (NASDAQ:AUPH) Sees Unusually-High Trading Volume

Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) saw strong trading volume on Tuesday . 1,142,602 shares traded hands during mid-day trading, a decline of 56% from the previous session’s volume of 2,577,490 shares.The stock last traded at $9.64 and had previously closed at $9.24.

Analyst Upgrades and Downgrades

A number of analysts have commented on AUPH shares. StockNews.com assumed coverage on Aurinia Pharmaceuticals in a report on Thursday, October 5th. They issued a “hold” rating for the company. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, September 22nd.

Aurinia Pharmaceuticals Stock Performance

The business has a 50-day moving average of $7.90 and a 200 day moving average of $9.33. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.77 and a quick ratio of 5.33. The company has a market cap of $1.41 billion, a PE ratio of -18.64 and a beta of 1.24.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Arizona State Retirement System grew its position in shares of Aurinia Pharmaceuticals by 2.8% during the 1st quarter. Arizona State Retirement System now owns 35,000 shares of the biotechnology company’s stock valued at $384,000 after acquiring an additional 968 shares during the period. Cetera Advisors LLC grew its stake in shares of Aurinia Pharmaceuticals by 2.4% during the 2nd quarter. Cetera Advisors LLC now owns 45,364 shares of the biotechnology company’s stock valued at $439,000 after acquiring an additional 1,065 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in Aurinia Pharmaceuticals by 11.2% during the second quarter. Ameritas Investment Partners Inc. now owns 11,183 shares of the biotechnology company’s stock valued at $108,000 after purchasing an additional 1,122 shares in the last quarter. Geneos Wealth Management Inc. boosted its position in shares of Aurinia Pharmaceuticals by 54.2% in the first quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 1,142 shares during the period. Finally, Great West Life Assurance Co. Can increased its stake in shares of Aurinia Pharmaceuticals by 22.3% in the first quarter. Great West Life Assurance Co. Can now owns 6,533 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 1,192 shares in the last quarter. Hedge funds and other institutional investors own 39.64% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.